Aim: There is limited information concerning the effects of canagliflozin (CANA), a sodiumglucose co-transporter 2 inhibitor (SGLT2i) in a real-world clinical setting in Canada. CanCARE is a 12-month, prospective, observational analysis to demonstrate the effectiveness and safety of CANA in usual clinical practice in Canada.
fastest growing chronic diseases, with parallel increases in incident and prevalent obesity. 4, 5 In 2015, the estimated prevalence of diabetes in Canada was 3.4 million, or 9.3% of the population, and is predicted to rise to 5 million, or 12.1% of the population, by 2025, which is a 44% increase from 2015 to 2025. 6 The cornerstone of T2DM management is achievement of sustained glycaemic control in order to prevent diabetic complications.
Despite the availability of multiple classes of antihyperglycaemic agents (AHAs), the results of the Diabetes Mellitus Status in Canada (DM-SCAN) survey highlighted the ongoing challenges faced by primary care physicians, with a persistent treatment gap associated with the management of TD2M in Canada, whereby only 50% of T2DM patients achieved HbA1c ≤ 7.0%. have been recognized and integrated into the T2DM treatment algorithm. 8, 9 These guidelines recommend a patient-centered approach to facilitate clinical decision making and selection of an AHA agent. As part of effective T2DM management, consideration of glycaemic efficacy, patient history of CV disease, vascular and renal benefits, impact on weight gain and hypoglycemia, as well as consideration of patient preferences, needs and values is suggested. 8, 9 Canagliflozin (CANA) is an orally active SGLT2i. Pharmacologic inhibition of SGLT2 is a unique mechanism that acts to decrease renal glucose reabsorption by lowering the renal threshold for glucose, leading to an increase in urinary glucose excretion (UGE) of 77-119 g/d
for CANA. This enhanced UGE lowers plasma glucose in individuals with elevated glucose concentrations and results in a loss of 308-476 kcal/d. 10, 11 The caloric loss leads to weight loss. Concomitantly, there is fluid loss, reflecting an osmotic diuresis and contributing to a reduction in both systolic and diastolic blood pressure. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] CANA has been evaluated in a broad range of patients with T2DM on a background of various AHAs, including monotherapy, add-on therapy with metformin (Met), sulfonylurea (SU), Met and SU and Met and pioglitazone, as well as add-on therapy with insulin, with or without other AHAs. 18 In addition, two head-to-head studies comparing CANA 300 mg to a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin) and to an SU (glimepiride) showed that it was significantly superior to these agents in reducing HbA1c over 12 months. 12, 15 Clinical trials evaluating CANA in older patients, in patients with moderate chronic kidney disease and in those with established CV disease, or who are at high risk for it, consistently demonstrated clinically relevant reductions in HbA1c, body weight and blood pressure (BP). [16] [17] [18] [19] In the CANVAS Program, CANA provided significant benefits in the reduction of CV events, in a decreased rate of hospitalization because of heart failure, and in a reduction in progression of albuminuria. 19 The CREDENCE trial, which was discontinued early because of positive efficacy findings, 20 will provide important insights concerning the effects of CANA in T2DM patients with diabetic nephropathy. 21 CANA has been studied extensively in randomized controlled clinical trials, [13] [14] [15] [16] [17] [18] [19] [20] [21] and in retrospective real-world analyses in the United
States. 22, 23 However, there is limited information concerning prospective outcomes in patients receiving CANA in a real-world setting that reflects Canadian practice. The present study prospectively evaluated CANA effectiveness and safety in the treatment of T2DM in the context of usual clinical practice in Canada.
| MATERIALS AND METHODS

| Study design and patient population
The aim of this prospective, multicentre study (was to evaluate treatment of T2DM with CANA in the setting of usual clinical practice in Canada. CanCARE (clinicaltrials.gov NCT02688075) is an observational study with pre-specified analyses for primary, secondary and exploratory outcomes. The results are presented descriptively as no formal hypotheses were pre-specified. initiation of CANA; or any condition that, in the opinion of the investigator, would make participation contrary to the best interest of the participant or could prevent, limit or confound the protocol-specified assessments.
The primary data source was the patient's medical records.
Patients who were willing to participate in the study signed a written informed consent form, confirming that they understood the procedures for data collection. Baseline data were collected at the study enrollment visit. As per study protocol, investigators reported diabetes-related complications (retinopathy, neuropathy, nephropathy, CAD, stroke or PVD) but were not required to provide further description or detailed history for this observational, real-world study.
The observational phase began at the time of CANA initiation and patients were followed for a maximum of 12 months. 
| Effectiveness outcomes
The primary outcome of the study was an estimation of mean change 
| Safety outcomes
The terms used by participating physicians to document adverse events (AE) were coded using the Medical Dictionary for Regulatory Activities (MedDRA, Version 19.1). AEs were summarized by system organ class and lowest-level term using the percentage of patients who experienced at least one occurrence of the given event.
Individual subject listings were to be provided for patients who 
| Statistical methods
The study population comprised all patients enrolled in the study who used CANA. A sample size of 385 patients allowed an estimation of the 95% CI for change in HbA1c from baseline at 6 months with a precision δ = 0.10 σ, where σ represents the value of the standard deviation of change in HbA1c from baseline in the population. It was assumed that the dropout rate would be approximately 15% every 6 months. Based on these estimates, a sample size of 535 patients was required to achieve the precision mentioned above.
The primary outcome of the study was an estimation of the mean change in HbA1c from baseline at 6 and 12 months. The 95% CIs were estimated for the change from baseline at 6 and 12 months using a mixed model, with the change from baseline as response, with month as main factor and with baseline HbA1c as covariate. In addition, pre-specified secondary outcomes were the effect of CANA on glycaemic control such as mean change in HbA1c from baseline at 3, 6 and 12 months and, stratified by baseline HbA1c (<7.5%, 7.5 to <8.5%, ≥8.5%), achievement of the composite endpoints BMI, weight and waist circumference.
For patients who discontinued use of CANA, only HbA1c values collected before discontinuation were included in the analyses. Analyses were carried out using the available data without any imputation of missing data. However, for sensitivity analysis of the primary outcome, interpolation and last observation carried forward (LOCF) were used to impute missing HbA1c values at 6 and 12 months. Primary outcome and all secondary continuous variables were summarized using descriptive statistics, including the number of observations, mean, standard deviations, ranges and 95% CIs for the mean. All secondary categorical variables were summarized using counts (n) and percentages (%).
3 | RESULTS
| Demographic and baseline characteristics
A total of 538 patients were screened for the CanCARE study, of whom 527 patients were enrolled at 28 Canadian sites and were included in the final analysis set for effectiveness and safety. Eleven (2.0%) patients were excluded from analysis because they did not meet one or more of the eligibility criteria. The number of participants for whom HbA1c data were available within the required reporting window of AE45 days was: baseline, 509; 3 months, 435; 6 months, 376 and 12 months, 321. Patient demographics are summarized in 
| Analyses of effectiveness
Significant improvements from baseline in mean HbA1c levels ( Figure 1(A) ).
Results from sensitivity analysis of the primary outcome, using
LOCF together with interpolation of data between visits to determine the response at target visits, were similar. In this analysis, the mean change in HbA1c from baseline at 6 and 12 months was −0.81 (95% CI The proportion of patients achieving a target HbA1c < 7%
increased steadily over time, reaching 38.6% by the end of study treatment (Figure 2(A) ).
Relative to baseline, mean body weight (Figure 1(B) ), mean waist circumference (Figure 1(C) ) and mean BMI (Figure 1(D) ) consistently HbA1c reduction ≥0.5% and 53% of patients with low HbA1c at baseline (7.0%-7.5%) reached this target. (Figure 2(B) ). Furthermore, significant reduction in HbA1c was observed, regardless of the background AHA used (Figure 2(D) ).
There were improvements in several measures of cardiovascular and metabolic parameters over the 12-month study (Table S1 ). In 
| Analyses of safety
A summary of AE incidence reported in this study is presented in Table 2 . In total, 200 of 527 patients (38.0%) reported 372 AEs. Four patients (0.7%) experienced fatal AEs (arrhythmia, cardiac arrest, esophageal varices and suicide), none of which was considered by the investigator to be related to the study drug. Among 527 patients, 54 (10.2%) discontinued study treatment; this was attributed mainly to genital fungal infections and polyuria which were the most frequently reported AEs.
The incidence of AESIs reported during the study was 14.8% and included severe hypoglycaemia (0.9%), genital mycotic infections Overall, at Month 12, 38.8% of patients achieved the HbA1c target of <7.0% and 72% of patients achieved a reduction in HbA1c of ≥0.5%.
Notably, 53% of patients with low HbA1c at baseline (7.0%-7.4%) achieved more than a half-point in HbA1c reduction. HbA1c reductions are more difficult to achieve in such patients compared to those with higher HbA1c levels, suggesting that CANA decreases HbA1c, even in patients with relatively low levels of hyperglycaemia.
Body weight, BMI and waist circumference were markedly reduced over time with use of CANA in this real-world study, which is consistent with published literature documenting the effects of CANA on body weight and modulation of visceral fat. 24 Abdominal or visceral adiposity is recognized as an independent predictor of metabolic and CV comorbidities. 25 Clinical studies concerning weight loss have shown the positive impact of weight reduction on lower cardiovascular risk factors such as lipids, BP and inflammatory markers. 26, 27 Findings from the STENO-2 study emphasized the importance of focusing on multifactorial risk reduction in T2DM management, on reduction of CV disease and renal impairment, as well as on improvement in treatment compliance in T2DM patients. 28, 29 Glycaemic control, weight loss and SBP reduction are known to markedly lower modifiable metabolic and CV-related risk factors, and are recognized as valid composite endpoints in assessing T2DM management. [30] [31] [32] In addition, changes in anthropometric measures are important and relevant to patients, and they have been associated with improvements in patient adherence to medication. 33, 34 Over the 12-month study period, 40% of patients achieved the double composite endpoint and approximately 25% of patients achieved triple target control (Figure 3 Consistent with the safety findings observed in CANA clinical trials, 12-18 the overall incidence of AEs was low, with most being either mild or moderate in severity. The vast majority of GMI and polyuria events occurred during the first 3 months after initiation of CANA treatment ( Figure S2 ) and declined over time in both men and women, similar to findings from Phase 3 clinical trials. 35 The study discontinuation rate associated with AEs was approximately 10%, with the most frequent reasons cited being genital fungal infection and polyuria (Table 2 ). The recent Diabetes Canada 2018 clinical practice guidelines underscore the importance of avoiding weight gain and hypoglycaemia with treatment selection in the management of T2DM. 10 Hypoglycaemia is a potential side effect of antihyperglycaemic therapies, particularly therapy with insulin and sulfonylureas, and is recognized as a major clinical consequence associated with falls, fractures and traffic accidents; it has also proven to be traumatic by causing fear, stress and anxiety for both the T2DM patient and the caregiver.
36,37
The observed renal threshold for glucose (RT G ) values with CANA treatment are above the usual threshold for hypoglycaemia (≤70.0 mg/dL or 3.9 mmol/L), a level above the plasma glucose concentration at which hypoglycaemic symptoms occur. 38 In our study, irrespective of different background AHA regimens (mono, dual or triple therapy, and in combination with insulin or other AHAs), the incidence of severe hypoglycaemia was very low (<1%) and occurred mainly in patients using insulin. This finding is in line with the clinical trial data available for CANA, in which hypoglycaemia was reported infrequently, and at rates similar to report rates for study comparator drugs. [13] [14] [15] [16] [17] [18] [19] A potential limitation of this prospective, observational registry is the open-label study design, which may have introduced selection bias related to the inclusion of patients who would most likely benefit from the CANA treatment. The lack of a control group is another limitation of the study; however, the findings from the current study supplement the growing body of evidence concerning significant real-world outcomes with CANA. 
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